Skip to main content

Research Repository

Advanced Search

Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling

Fellows, AL; Quigley, K; Leung, V; Ainscough, AJ; Wilkins, MR; Barnett, H; Miller, D; Mayr, M; Wojciak-Stothard, B

Authors

AL Fellows

K Quigley

V Leung

AJ Ainscough

MR Wilkins

H Barnett

D Miller

M Mayr

B Wojciak-Stothard



Abstract

Background and PurposeVasoreactivity of pulmonary arteries regulates blood flow through the lungs. Excessive constriction of these vessels contributes to pulmonary arterial hypertension (PAH), a progressive and incurable condition, resulting in right heart failure. The search for new and improved drug treatments is hampered by laboratory models that do not reproduce the vasoactive behaviour of healthy and diseased human arteries.Experimental ApproachWe have developed an innovative technique for producing miniature, three-dimensional arterial structures that allow proxy evaluation of human pulmonary artery contractility. These "engineered pulmonary artery tissues" or "EPATs" are fabricated by suspending human pulmonary artery vascular smooth muscle cells (VSMCs) in fibrin hydrogels between pairs of silicone posts, located on custom-made racks, in 24-well culture plates.Key ResultsEPATs exhibit rapid, robust and reproducible contraction responses to vasoconstrictors (KCl, ET-1, U46619) as well as relaxation responses to clinically approved PAH vasodilatory drugs that target several signalling pathways, such as bosentan, epoprostenol, selexipag and imatinib. EPATs composed of pulmonary artery VSMCs from PAH patients exhibit enhanced contraction to vasoconstrictors and relaxation in response to vasodilators. We also demonstrate the incorporation of endothelial cells into EPATs for the measurement of endothelium-dependent dilatory responses.Conclusion and ImplicationsWe demonstrate the capacity and suitability of EPATs for studying the contractile behaviour of human arterial cells and preclinical drug testing. This novel biomimetic platform has the potential to dramatically improve our understanding and treatment of cardiovascular disease.

Citation

Fellows, A., Quigley, K., Leung, V., Ainscough, A., Wilkins, M., Barnett, H., Miller, D., Mayr, M., & Wojciak-Stothard, B. (2025). Engineered pulmonary artery tissues for measuring contractility, drug testing and disease modelling. British Journal of Pharmacology, https://doi.org/10.1111/bph.17462

Journal Article Type Article
Acceptance Date Dec 19, 2024
Online Publication Date Feb 20, 2025
Publication Date 2025
Deposit Date Mar 18, 2025
Publicly Available Date Mar 18, 2025
Print ISSN 0007-1188
Electronic ISSN 1476-5381
Publisher Wiley
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1111/bph.17462
Keywords bioengineering; disease modelling; drug testing platform; pulmonary hypertension; vascular pharmacology; SMOOTH-MUSCLE-CELL; HYPERTENSION; RAT; VASOCONSTRICTOR; MECHANISMS; PHENOTYPE; MOUSE; GUIDE

Files




Downloadable Citations